Sandoz Group AG (SDZNY) Stock Price & How to Invest

Sandoz Group AG makes off-patent medicines: generics, which copy small-molecule drugs once their patents expire, and biosimilars, which are near-copies of complex biologic drugs such as antibodies. It sells about 1,300 medicines, from antibiotics and cough remedies to cancer and immunology treatments, and employs more than 20,000 people. Net sales were $11.1B in 2025. In the first half of 2026 net sales were $5.76B, up 5% at constant currencies: generics brought in $3.89B (67%) and biosimilars $1.88B (33%, up from 29% a year earlier). By region, Europe is the core at $3.13B (54% of first-half sales), followed by International at $1.34B and North America at $1.30B, which was the fastest-growing region at +15% at constant currencies. The ten largest medicines grew 14% combined and made up 35% of sales.

The company traces its roots to 1886, when the chemical firm Kern & Sandoz was founded in Basel. Sandoz merged with Ciba-Geigy in 1996 to form Novartis, which later used the Sandoz name for its generics arm. In 2006 Sandoz won approval for Omnitrope (somatropin), the world's first approved biosimilar. Novartis spun Sandoz off on October 4, 2023, giving shareholders one Sandoz share for every five Novartis shares, and Sandoz listed on the SIX Swiss Exchange under SDZ. It joined Switzerland's blue-chip SMI index on September 21, 2026. Recent deals include the December 2025 purchase of Just-Evotec Biologics EU, a biosimilar development and manufacturing site in France, for $274M, and an agreement with Samsung Bioepis for up to five biosimilar assets, including vedolizumab.

Richard Saynor is CEO and Gilbert Ghostine chairs the board. Because the shares were distributed to Novartis's broad investor base, there is no controlling shareholder. US investors can hold the company through SDZNY, a sponsored Level I American Depositary Receipt program with J.P. Morgan as depositary, quoted on the OTCQX market. Each ADR represents one ordinary share, so the ADR price tracks the Swiss franc share price converted into dollars. Dividends are declared in Swiss francs and paid to ADR holders in dollars after Switzerland's 35% withholding tax, part of which US holders can generally reclaim under the US-Swiss tax treaty.

The investment case is a mix shift. Generics are a high-volume business where prices fall every year; Sandoz now expects overall pricing to drop by a mid-single-digit percentage in 2026. Biosimilars carry better margins, and Sandoz is putting money behind them, including new plants in Slovenia. Core EBITDA rose 15% in dollars to $1.21B in the first half of 2026, a 20.9% margin, and core diluted earnings per share rose 17% to $1.71. Reported net income fell to $109M from $377M because of $470M of legal expenses tied to old US generic-pricing antitrust cases. Net debt was $3.55B at the end of June 2026, and the market value is about $37B at ~$84 per ADR.

Price erosion is the constant risk in generics. Sandoz raised its 2026 expectation for overall price decline to a mid-single-digit percentage, citing short-term market dynamics in Germany and strong North American biosimilar volumes that carry their own discounts, and first-half volume growth of 10% was offset by 5% price erosion. Biosimilar launches draw several rivals at once, so the denosumab gains may face tougher pricing as more competitors arrive. The anti-infectives business is exposed to Chinese penicillin ingredient makers, who cut global prices for key ingredients such as 6-APA after US tariffs in 2025 reduced their exports to the US; that hit first-quarter 2026 sales. Guidance excludes the possible effect of new US tariffs, and Sandoz manufactures heavily in Europe. Legal costs remain material: first-half 2026 reported net income was $109M against $750M of core net income, largely because of $470M in legal expenses, and opt-out antitrust claims are still pending. The heavy Slovenian build-out raises capital spending and execution risk before the plants contribute. Sandoz reports in dollars but earns more than half its sales in Europe and pays dividends in Swiss francs, so currency moves affect reported growth and what ADR holders receive. The 2030 and 2035 targets depend on regulators and courts letting biosimilars reach market on schedule, and long-range ambitions can slip. SDZNY itself trades over the counter, where volume is lower than on the SIX Swiss Exchange, and US holders lose part of each dividend to the 35% Swiss withholding tax unless they file a reclaim.

We give no verdict on Sandoz Group AG. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Biosimilar growth and the Bio100 plan. Biosimilar sales grew 20% at constant currencies in the first half of 2026 and 22% in the second quarter, with every region contributing.

The case against. Price erosion is the constant risk in generics.

Read the full bull and bear case on SDZNY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Sandoz Group AG's investor relations page or your broker.

• Net sales (TTM to June 2026): ~$11.6B
• Net sales (H1 2026): ~$5.76B (+5% at constant currencies)
• Core EBITDA (H1 2026): ~$1.21B (20.9% margin)
• Core diluted EPS (H1 2026): ~$1.71 (reported net income ~$109M)
• Net debt: ~$3.55B (June 30, 2026)
• Market cap: ~$37B (SDZNY ~$84, SDZ ~CHF 70)

Trailing sales of ~$11.6B (2025's $11.1B, less the first half of 2025, plus the first half of 2026) put the company at a bit over 3 times sales. The gap between core and reported earnings is wide this year: core net income was $750M in the first half against reported net income of $109M, with legal provisions, restructuring and separation costs making up most of the difference. Net debt of $3.55B is modest next to roughly $2.4B of annualized core EBITDA. The dividend of CHF 0.80 per share for 2025, up from CHF 0.60, works out to a yield of a little over 1% before Swiss withholding tax. Margin progress toward the 25% to 27% 2030 target is the main thing the valuation is waiting on.

Other names that sit close to SDZNY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SDZNY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SDZNY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SDZNY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

SDZNY gives US investors a dollar-quoted claim on a large, cash-generating off-patent drug business that is tilting toward higher-margin biosimilars. The price paid for that shift is steady price erosion in generics, a heavy capital program and legacy US legal costs.

Whether SDZNY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SDZNY a buy or a sell?, and where the stock could go from here in the SDZNY stock forecast.

For income investors, whether SDZNY pays a dividend and how the payout looks is covered in does SDZNY pay a dividend? And to weigh SDZNY against a peer, read the full side-by-side comparisons: SDZNY vs VTRS and SDZNY vs AMRX.